1. Home
  2. DEO vs ARGX Comparison

DEO vs ARGX Comparison

Compare DEO & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Diageo plc

DEO

Diageo plc

HOLD

Current Price

$87.14

Market Cap

53.6B

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$1,007.07

Market Cap

58.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DEO
ARGX
Founded
1886
2008
Country
United Kingdom
Netherlands
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.6B
58.4B
IPO Year
2001
2017

Fundamental Metrics

Financial Performance
Metric
DEO
ARGX
Price
$87.14
$1,007.07
Analyst Decision
Buy
Strong Buy
Analyst Count
2
19
Target Price
$109.00
$1,008.56
AVG Volume (30 Days)
909.1K
260.4K
Earning Date
02-25-2026
05-07-2026
Dividend Yield
4.18%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$2.65
$44.39
Revenue Next Year
N/A
$20.84
P/E Ratio
$90.04
$33.69
Revenue Growth
N/A
N/A
52 Week Low
$72.45
$661.85
52 Week High
$102.47
$1,072.75

Technical Indicators

Market Signals
Indicator
DEO
ARGX
Relative Strength Index (RSI) 40.00 55.77
Support Level $87.09 $830.58
Resistance Level $87.48 N/A
Average True Range (ATR) 1.45 23.70
MACD -0.99 -2.27
Stochastic Oscillator 1.82 20.51

Price Performance

Historical Comparison
DEO
ARGX

About DEO Diageo plc

Formed in 1997 through the merger of Grand Metropolitan and Guinness, Diageo is the largest distiller globally by sales. Diageo acquired some of the Seagram assets in 2001, which gave it brands such as Captain Morgan rum and Crown Royal Canadian whisky. Since then, mergers and acquisitions have mostly been bolt-on in nature, plugging gaps in the company's product and geographic portfolio.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: